IDENTIFICATION OF SELECTED PERSONNEL (U)

• Document Type: CREST
• Collection: STARGATE
• Document Number (FOIA) /ESDN (CREST): CIA-RDP96-00792R000100140042-6
• Release Decision: RIFPUB
• Original Classification: S
• Document Page Count: 9
• Document Creation Date: November 4, 2016
• Document Release Date: October 28, 1998
• Sequence Number: 42
• Publication Date: August 2, 1983
• Content Type: MEMO

Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
August 2, 1983
SUBJECT: Identification of Selected Personnel (U)
Dr. Harold E. Puthoff
SRI International
333 Ravenswood Avenue
Aenlo Park, California 94025
f
(S/CL-l/NOFORN) Reference your memorandum, dated 11 fay.
1563, Subject: Selection/Training Task.
(U) The attached draft Statement of Work is forwarded for
your review.
(S/CL-l/NOFORN) Request specific cost, expected length of
each phase and any recommended additions which may be necessary
within the Statement of Work as drafted.
(U) To allow sufficient time to meet administrative
requirement for funding in FY 83, request an expeditious
response.
Sincerely,
rUderick H. Atwater
Acting Project Manager
CLASSIFIED BY: CG, INSCOL
DECL: OADR
WARNING NOT ICE
CENTER LANE SPECIAL ACCESS PROGRA I
RESTRICT DISSEMINATION TO THOSE WITH VERIFIED ACCESS
CATEGORY 3
NOT R IEa SABL TO M O RIOI4 #rAI O IALS
or Release 200%WLI q - A DP96-00792R000100140042-6
U'i
 1. (U) GENERAL
1.1 (S/CL-3/NOFORN/ORCON) The objective of this effort is
to investigate a particular aspect of psychoenergetics relating
to operational management of personnel. That is; determine if a
personality testing technique can be created which when applied
to a general population will delineate specific individuals who
exhibit a higher degree of talent for Remote Viewing (RV).
1.2 (U) MAJOR GOALS ARE:
(a) (S/CL-3/NOFORN/ORCON) PHASE I: Apply personality
testing with proven remote viewer personnel from SRI and Project
CENTER LANE; and determine testing profile(s) which can be used
to identify personel with an aptitude for remote viewing.
(b) (S/CL-3/NOFORN/ORCON) PHASE II: Test these same
individuals with "self-report" type tests, and compare the
results of these with the previously identified profile(s) to
determine testing accuracy. Apply the identified profile(s)
against a general test population and segragate persons who show
a talent for remote viewing from those who do not.,
(c) (S/CL-3/NOFORN/ORCON) PHASE III: Test the
personnel who show a talent for remote viewing against randomly
selected targets; test the personnel who did not show a talent
against the same targets.
(e) (S/CL-3/NOFORN/ORCON) Provide an overall
evaluation of the above three Phases with conclusive
recommendations. If the first two Phases produce negative
results; an overall evaluation of those two phases will be made
to include a recommendation for further action.
2. (U) SPECIFIC TASKS:
2.1 (U) PHASE I - As follows:
(a) (S/CL-R3/NOFORN/ORCON) Collect personality profile
data from proven remote viewers. Data will be collected from
proven personnel; both at SRI as well as Project CENTER LANE.
NOT RE EAS.ABLE TO FOE ION NATIONALS
L
SEC!ET.
Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
 Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
(b) (U) Data will be collected by using an extended
Wechsler Test.
(c) (U) Testing will be carried out under laboratory
conditions by two experienced testors; Dr. David Saunders, MARS
Measurements Association (SRI Consultant), Lawrenceville, New
Jersey; and Dr. Michael Hecker (an SRI Staff Member.)
(d) (U) The data obtained will be analyzed in
accordance with the P. A. S. (Personality Assessment System)
concept.
(e) (U) The above analysis will provide the basis upon
which specific and appropriate personality profile(s) of
interest will be designated and those will be extrapolated for
use during PHASE III.
(f) (U) Provide an interim report of findings from
2.2 (U) PHASE II - Will be run in parallel with PHASE I
and includes the following:
(a) (S/CL-2/NOFORN/oRCON) Self-report data will be
collected from the selected individuals within SRI and the
CENTER LANE Project. These will be the same individuals
selected for testing under PHASE I.
(b) (U) The self-report data will be determined from
tests such as the Myers-Briggs and 16 PF questionnaire. Testing
will be under laboratory conditions and will be utilized to
design a pre-screening questionnaire.
(c) (U) Analysis of the self-report data will be
carried out using the B. P. S. (Behavior Prediction System)
concept to generate a scoring key capable of extracting those
individuals with profile(s) indicated within PHASE I, as being
profile(s) of interest.
(d) (S/CL-3/NOFORN/ORCON) The self-report test
criteria will be applied against a general population. The
general population will contain the previously selected SRI and
CENTER LANE Remote Viewer personnel.
(e) (U) To test whether the pre-screening
(self-report) test is effective in selecting individuals with
the PHASE I profiles, a second group of individuals will be
given both the pre-screening and extended Wechsler tests under
like laboratory conditions and the correlations between these
results and the previous results will be evaluated and examined.
N02 t 'LE.1& ABLE T0 s: OI .IU`iW
elease 2003/0C c A RF P96-00792R000100140042-6
 Approved For Release 2003/09/1 Q CiDP96-00792R000100140042-6
(f) (U) Provide an interim report of findings from
PHASE Ii.
2.3 PHASE III - Assuming success in Phases I and II the
following will be accomplished:
(a) (S/CL-3/NOFORN/ORCON) The appropriate profile(s)
developed through testing during PHASES I & II will be used to
delineate individuals into two groups. Those with remote
viewing potential as well as those who do not show potential.
(b) (S/CL-3/NOFORN/ORCON) Personnel who show potential
in remote viewing will then be tested under laboratory
conditions against a randomly selected group of targets.
(c) (S/CL-3/NOFORN/ORCON) Personnel not selected as
having potential will also be run under laboratory conditions
against the same selected group of targets.
(d) (S/CL-3/NOFORN/ORCON) A comparison of both groups
of personnel will then be made to determine the validity of
slection criteria developed and presented from PHASES I & II.
(e) (S/CL-3/NOFORN/ORCON) Should it be proven by
failure in PHASES I & II that a personality profile cannot be
developed which will assist in selecting appropriate remote
viewer personnel; then PHASE III will be canceled with the
concurrance of the sponsor and all monies left transfered to
on-going remote viewer training.
3. (U) SECURITY
Military security requirements in the performance of this
contract shall be maintained in accordance with the CENTER LANE
SECURITY PROCEDURES GUIDE, dated; 01 March 1983 (S/CL-l/NOFORN
ORCON); and DD Form 254 attached hereton. The highest
classification involved in the performance of this contract is
SECRET/CL-4/NO FOREIGN DISSEMINATION/ORIGINATOR CONTROLLED.
4. (U) DELIVERABLES: The contractor will provide the
following:
4.1 (S/CL-l/NOFORN/ORCON) State-of-the-art information on
selection of personnel with a talent for Remote Viewing (RV).
4.2 (S/CL--3/NOFORN/ORCON) Progress report (2 copies): A
written evaluation of findings within 10 days of completion of
Phase I, development of/and use of psychological profile(s)
testing.
P'll
RGL s..7.PiliLL' 1 FO EI r RIT!
Approved For Release 200 0.~ ;'3IA DP96-00792R000100140042-6
 Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
4.3 (S/CL-3/NOFORN/oRCON) Progress report (2 copies): A
written evaluation of findings within 10 days of completion of
Phase II, development of/and use of self-report testing; to
include comparison for accuracy against Phase I testing, and use
of the newly designed pre-screening questionnaire.
4.4 (S/CL-3/N0FORN/OR(,'ON) A final report (3 copies) will
be furnished within 30 days following completion of the overall
evaluation of developed Selection Testing Methodology. Report
will include but is not limited to the following:
(a) (S/CL-3/NOFORN/ORCON) Report will include a
summary of tests performed in each methodology area; an
evaluation of those tests; and a written comparison of one test
methodology to another.
(b) (S/CL-3/NOF0RN/oRCON) Report will provide findings
which result from the application of testing methodologies
against a general population to select remote viewers. This
will include an evaluation of remote viewing results as produced
by those personnel identified as talented, as well as results
from those who were not identified as talented.
(c) (S/CL-3/NOFORN/0RCON) Report will provide a
summary of recommended testing for future selection of remote
viewer personnel based upon the above.
6. (U) SPECIAL REQUIREMENTS
6.1 (U) Use of Human subjects:
(a) (U) The following definitions are used:
(1) (U) At risk means that the human subject may be
exposed to the possibility of harm - physical, biological,
psychological, sociological, or other as a consequence of an act
or omission that goes beyond the application of those
established and accepted methods or procedures which are in his
best interests, or that increases ordinary risks of daily life,
including the recognized risks inherent in his chosen occupation
or field of service.
(2) (U) Human subject means a.ny human being who,
knowingly or unknowingly, is subjected to an act or omission,
whether at risk or not, the object of which is to contribute to
knowledge to be gained as a part of work to be performed under
the scope of this contract.
pproved For Release 2003/09/10: CIA-RDP, ,6 0792R000100140042-6
 Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
(b) (U) The contractor, before undertaking to perform
any study involving human subjects, whether at risk or not,
shall insure that the following minimum conditions are complied
with:
(1) (U) The proposed study has been reviewed and
approved by a committee meeting the requirements set forth in
Chapter 46 of Title 45 of the Code of Federal Regulations.
(2) (U) The number of human subjects used will be kept
to the minimum number that will reasonably achieve the required
results.
(3) (U) The study must be such as to contribute
significantly to scientific knowledge and have reasonable
prospects of yielding important results essential to an Army
research program.
(4) (U) The study will be conducted only by persons
possessing the requisite scientific qualifications. The highest
degree of skill and care will be required during all stages of
study of persons who conduct or assist in the study.
(5) (U) The subject will be informed that at any time
during the course of his participation he has the right to
revoke his consent and withdraw from participation without
prejudice to himself.
(6) (U) Participation by subjects will be immediately
terminated if it subsequently appears that the risk to the
subjects is significantly greater than anticipated at the time
review and approval was granted.
(7) (U) There shall be no greater intrusion into the
privacy of the human subject than is absolutely necessary for
the conduct of the study involved. Except for the submission of
reports and other data required by this contract, any
information obtained about human subjects as a result of
participation shall be held as confidential as the law allow.
(8) (U) The study will be conducted so as to avoid all
unnecessary physical or mental suffering or injury.
(9) (U) No study will be conducted if there is any
inherent reason to believe that death or disabling injury is
likely to occur. Sufficient animal or laboratory experiments,
or other evaluations, must have been completed to give assurance
of acceptable risks prior to the use of human subjects.
NOT -RELEA5 BLE -u Lzi .211, 11 y
03/09/10 : CIA-RDP96-00792R000100140042-6
 Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
(10) (U) The degree of risk to be taken will never
exceed that which is justified by the benefit to the subject
and/or the humanitarian importance of the knowledge to be gained.
(11) (U) A physician will be responsible for the
medical care of subjects. Even if not the project leader, the
physician will have authority to terminate the study at any time
that he believes death, injury or harm is likely to result.
(12) (U) Proper preparations will be made, and
adequate facilities provided to protect the subject against all
foreseeable possibilities if injury, disability or death. This
includes but is not limited to hospitalization and medical
treatment as may be required. In addition, all apparatus and
instruments necessary to deal with likely emergency situations
will. be available,
(13) (U) Human subjects will have no physical or
mental conditions which will make participation more hazardous
for them than it would be for normal healthy persons, unless
such condition is a necessary prerequisite for the particular
study involved. In any such case, the use of human subjects
with such pre-existing conditions must have been specifically
described and justified in the scope of the work to be performed
under this contract.
(14) (U) The scientifically qualified person
conducting the study, and each member of his research team, will
be prepared to terminate the subject's participation at any
stage if he has reason to believe, in the exercise of the good
faith, superior skill, and careful judgment required of him,
that continuation is likely to result in injury, disability, or
death to the human subject.
(c) (U) The contractor, before permitting any person
to participate as a human subject, whether at risk or not, shall
insure that the following minimum conditions are complied with:
(1) (U) Legally effective informed consent will be
obtained by adequate and appropriate methods in accordance with
the provisions of this clause.
(2) (U) All consent must be voluntary. It must be the
knowing consent of the individual or his legally authorized
representative, so situated as to be able to exercise free power
of choice without there having been any use of force, fraud,
deceit, duress, constraint, coercion, or lawful or improper
inducement. The elements of information necessary to such
consent include:
N0T RuLL~iSAB~ B) I Yi 5 S Li Yiai~ \ cis e
or Release 20''i . -RDP96-00792R000100140042-6
 Approved For Release 2003/09/10 : CIA-RDP96-00792R000100140042-6
(i) (U) A fair explanation of the procedures to be
followed, and their purposes, including identification of any
procedures which are experimental.
(ii) (U) A description of any attendant discomforts or
risks reasonably to be anticipated.
(iii) (U) A description of any benefits reasonably to
be anticipated.
(iv) (U) A disclosure of any appropriate alternative
procedures that might be advantageous to the subject.
(v) (U) An offer to answer any questions concerning
the procedure.
(vi) (U) An instruction that the subject is free to
revoke his consent and to discontinue participation at any time
without prejudice to himself.
(d) (U) Exculpatory language through which the subject
is made to waive, or appear to waive, any of his legal rights,
including any release from liability for negligence, is
prohibited.
(e) (U) Prior consent by a subject or his legally
authorized representative shall be obtained in all cases. Such
consent shall be in writing whenever it is reasonably possible
to do so. The consent form may be read to the subject or his
legally authorized representative, but in any event he or his
legally authorized representative must be given adequate
opportunity to read it and to ask questions they might have.
This consent form should then be signed by the subject or his
legally authorized representative and by a witness not directly
involved in the study. Oral consent may be used only when it
has been specifically described and justified in the scope of
the work to be performed under this contract or approved in
writing by the contracting officer. When so authorized and
used, oral consent is subject to all the same standards as apply
to written consent, except that the signature of the subject or
his legally authorized representative is not required.
(f) (U) Prior to conduct of the study, the contractor
shall submit for approval to the contracting officer's
representative a detailed description of the means by which
informed consent will be obtained, to include any forms to be
used. Upon completion of the study, the contractor will submit
to the contracting officer's representative a detailed report
demonstrating compliance with paragraph (c), to include copies
of the written consent if such was obtained.
Approved For Release 2003/09/:10 : CIA-RDP06-00792R000100140042-6
 Approved For Release 2003/09/10 : CIA RRDP96-00792R000100140042-6
(g) (U) The contractor shall not undertake to conduct
either the clinical pharmacology or clinical trails of an
investigational drug unless this contract contains the clause
entitled "Clinical Study of Investigational Drugs."
(h) (U) Prisoners of war will not be used under any
circumstances.
6.2 (U) DOD Directive 5240.1-R governing experimentation
on human subjects will be followed by the contactor. Informed
consent of all subjects will be obtained in writing in
accordance with the guidelines issued by the Department of
Health, Education and Welfare. All persons participating as
human subjects, as defined in paragraph 6.1 above shall be known
to possess the abilities and qualities which will be observed
and analyzed during the conduct of this contract.
NOT B'ET,E/ISABLE ?O FCEEIGN
Approved For Release 2003/09/101:>.CIA-R6P96-00792R000100140042-6